オプションチェーンは、IDEAYA Biosciencesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、IDEAYA Biosciencesの市場センチメントを評価します。.

IDEAYA Biosciences (NASDAQ:IDYA) 株価情報, オプションチェーン

IDEAYA Biosciences

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

IDEAYA Biosciences Inc

WIIM

WillScot Holdings shares are trading higher following a report suggesting activist investor TOMS has built a stake in the company and is pushing for a review.

JP Morgan analyst Kevin Yin upgrades Yum China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) from Neutral to Overweight and raises the price target from $35.5 to $60.

News

Upgrades

Price Target

Analyst Ratings

YUMC

JP Morgan Upgrades Yum China Holdings to Overweight, Raises Price Target to $60

With the first polling places about to close in what is <a href="https://www.benzinga.com/general/politics/24/11/41748843/trump-holds-edge-in-betting-markets-on-election-day-while-experts-call-tight-race-for-harris">expected to be a neck-and-neck election night</a>, reports from Georgia and Michigan say those two swing states are seeing record-high turnout.
What Happened: Turnout in Philadelphia is also reported to be extremely high, with Reuters reporting turnout as much as 50% higher in some precincts than in 2020. A big win in Philadelphia would go a long way toward delivering Pennsylvania &#8211; the largest and tightest swing state &#8211; to Kamala Harris.
At 4:39 p.m. EDT, Donald Trump wrote on Truth Social: &#8220;A lot of talk about massive CHEATING in Philadelphia. Law Enforcement coming!!!&#8221; 
A Philadelphia police spokesman <a href="https://fortune.com/2024/11/05/donald-trump-claims-cheating-police-philadelphia-pennsylvania/">told Fortune</a> they are &#8220;not aware of anything at this time.&#8221; 
Charlie Kirk of pro-Trump group Turning Point Action wrote earlier on X: &#8220;Turnout is mixed and not where we want it to be. We need more people to vote.&#8221;
Also Read: <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">2024 Election Stakes: Potential Sweeps, Split Outcomes In Congressional, Presidential Races</a>
Politico is <a href="https://www.politico.com/live-updates/2024/11/05/2024-elections-live-coverage-updates-analysis/turnout-high-in-georgia-00187458">reporting</a> that turnout in Georgia is on track to surpass 2020, and The Hill <a href="https://thehill.com/homenews/campaign/4973132-michigan-on-pace-to-break-voter-turnout-records-official-says/">says</a> that Michigan may break turnout records.
Why It Matters: High turnout in Philadelphia would be good news for Harris, but even a loss in Pennsylvania would not be fatal to Trump if he performs well in other swing states.
Georgia, Michigan and Pennsylvania were all key to Joe Biden&#8216;s victory in 2020.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">Trump Vs. Harris: 2024 Election Deadlocked, Final Emerson Poll Shows One Candidate With Small Edge Among Independents</a></li>
</ul>
Image: Shutterstock.

Politics

High Turnout Reported In Key States, Trump Baselessly Alleges 'Massive CHEATING' In Philadelphia

A new study <a href="https://tandfonline.com/doi/full/10.1080/21507740.2024.2303154">published</a> in AJOB Neuroscience reveals that most Americans are supportive of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost <a href="https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/">reported</a>, this approval, spanning across political lines, underscores public openness to the controlled use of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin for mental health treatment</a> and general well-being, despite remaining concerns for policy caution.
Psilocybin, a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule 1</a> drug in the U.S., has long been classified as having a high potential for abuse with no accepted medical use. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">recent clinical studies</a> suggest it may help alleviate symptoms of conditions such as treatment-resistant depression when administered under professional supervision. Unlike many medications, psilocybin is considered non-addictive, and studies have found it may also <a href="https://www.benzinga.com/markets/cannabis/24/09/41004196/psilocybin-found-to-be-as-effective-as-lexapro-in-treating-depression-researchers-say">enhance overall well-being</a> in healthy individuals.
This research aimed to explore public perceptions of psilocybin amid <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">recent legislative progress</a>, such as Oregon&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">allowing its therapeutic use</a>. Researchers surveyed 805 Americans, aged 18 to 92, providing background on psilocybin's effects, origin and legal status before asking about support for nationwide legalization.
<h3 class="wp-block-heading">Mental Health Treatment Vs. Well-Being Enhancement</h3>
Participants were presented with two scenarios involving supervised psilocybin use: one for mental health treatment and the other for personal well-being. A strong 89% of participants supported psilocybin use for mental health treatment, while 85% approved its use for well-being enhancement. Though medical use garnered slightly more support, both scenarios saw broad endorsement.
The results show bipartisan support for supervised psychedelic therapy, with younger and more liberal adults showing stronger approval. Older adults and conservatives were more cautious, while those valuing empathy and care were more supportive of psilocybin use in therapy
<h3 class="wp-block-heading">Navigating Caution Amid The Psychedelic Renaissance</h3>
The study also sheds light on the importance of tempering enthusiasm with scientific rigor. According to the researchers, the growing interest in psychedelics comes with the risk of overhyping benefits. Given the early stage of the field, both over- and understatements of trial results are not uncommon. As they noted, while psilocybin shows significant medical potential and a strong safety profile, current evidence doesn&#8217;t support rash conclusions beyond its use in the right context.
While the findings suggest broad public support for supervised psychedelic use, the study focused only on licensed environments, excluding unsupervised or recreational use. Future research could explore attitudes toward these higher-risk aspects.
<h3 class="wp-block-heading">Building Trust And Policy For The Future</h3>
The study authors stressed the need for trust-building and caution in shaping future policies. "If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust—then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being," they concluded.
With public support reaching bipartisan levels, the potential for psilocybin to become part of standard mental health care is closer to reality than ever, signaling a transformative shift in mental health treatment in the U.S.
Cover image made with AI

Cannabis

Psychedelics

Americans Favor Psilocybin For Mental Health Treatment, Study Finds

DA Davidson analyst Brian Holland maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $183 to $189.

FRPT

DA Davidson Maintains Buy on Freshpet, Raises Price Target to $189

Hut 8 Says Its Self-Mining Produced 100 BTC In October, Up From 85 BTC In September; Vega Site Buildout Advancing On Track For Q2 2025 Energization

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and lowers the price target from $94 to $90.

DA Davidson Maintains Neutral on Federal Signal, Lowers Price Target to $90

DA Davidson maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $55 to $48.

NSSC

DA Davidson Maintains Buy on NAPCO Security Techs, Lowers Price Target to $48

Emerson and its affiliates currently own 57.4% of the Company's outstanding common shares, based on their most recent Schedule 13D filing dated November 5, 2024.
The Board of Directors of AspenTech will follow an appropriate governance process and carefully review the proposal. No action is required by AspenTech shareholders at this time. &nbsp;

AZPN

Aspen Technology Confirms Receipt Of $240/Share Unsolicited Acquisition Proposal From Emerson; Asks Shareholders Not To Take Any Action Pending Review

DA Davidson analyst Brent Thielman maintains Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) with a Neutral and raises the price target from $41 to $47.

DA Davidson Maintains Neutral on Summit Materials, Raises Price Target to $47

Guidance

PAAS

Pan American Silver Reaffirms Its 2024 Operating Outlook For Annual Production, Cash Costs And AISC, And Capital Expenditures

Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 3100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $716.10 million which beat the analyst consensus estimate of $699.01 million by 2.44 percent. This is a 16.19 percent increase over sales of $616.30 million the same period last year.

Earnings

Earnings Beats

Pan American Silver Q3 2024 Adj EPS $0.32 Beats $0.21 Estimate, Sales $716.10M Beat $699.01M Estimate

DA Davidson analyst Kevin Fitzsimmons maintains Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) with a Buy and lowers the price target from $41 to $38.

DA Davidson Maintains Buy on Origin Bancorp, Lowers Price Target to $38

DA Davidson analyst Gil Luria maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Neutral and raises the price target from $28 to $47.

PLTR

DA Davidson Maintains Neutral on Palantir Technologies, Raises Price Target to $47

The 2024 U.S. presidential election between Vice President Kamala Harris and former President Donald Trump remains one of the closest in history, raising concerns over whether the U.S. Supreme Court may play a decisive role in <a href="https://www.benzinga.com/topic/2024-election">determining the outcome. </a>
As voters head to the polls, election-related legal battles already hint at the possibility of judicial involvement, The New York Times <a href="https://www.nytimes.com/2024/11/05/us/politics/election-supreme-court.html">reports</a>.
What Happened: Several election cases have reached the Supreme Court in recent weeks, including a decision to allow Virginia's removal of over 1,600 voters from its rolls and rulings affecting candidates and voters in battleground states. 
The court decided against removing Robert F. Kennedy Jr. from ballots in key states and authorized provisional ballots in Pennsylvania, after some mail-in ballots were deemed invalid. These cases showcase the judiciary's cautious approach to electoral involvement, although the court's conservative majority could still play a critical role if a close race sparks significant litigation, according to The New York Times.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41759661/us-election-jitters-meet-interest-rate-cut-assurance-why-feds-powell-may-offer-tr">US Election Jitters Meet Interest-Rate Cut Assurance: Why Fed&#8217;s Powell May Offer Traders A Safe Harbor This Week</a>
The Supreme Court's involvement would hinge on an exceptionally narrow vote margin in a critical state, experts say. Prof. Richard Pildes of New York University told The New York Times that a paper-thin margin in a state like Pennsylvania, with its 19 electoral votes, could increase the likelihood of a court ruling influencing the presidential outcome.
Still, experts are cautious, noting that the Supreme Court generally aims to avoid direct involvement in elections.
Beyond the presidential race, the stakes extend to congressional control. Democrats seek to retain the Senate and flip the House, while Republicans push for gains in both chambers. The outcomes in Senate races, including those in Montana and Ohio, could shift control, particularly if Democratic seats in battleground states like Michigan and <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">Pennsylvania face Republican challenges.</a> 
Why It Matters: A Supreme Court decision might not only impact the presidency but also influence control over Congress, setting a precedent for election litigation. In a scenario reminiscent of the Bush v. Gore case in 2000, if margins are close enough, legal challenges could escalate to the highest court. 
The potential for either party to control both chambers or split Congress suggests significant implications for the future of U.S. legislation and governance, The New York Times notes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41756372/robinhoods-election-contracts-hit-200-million-trades-on-election-day">Robinhood&#8217;s Election Contracts Hit 200 Million Trades On Election Day</a></li>
</ul>
This article was generated using artificial intelligence and was reviewed by Benzinga editors.
Photo: Shutterstock

Government

Legal

Supreme Court Could Step In If 2024 Election Remains Deadlocked

SMCI

Super Micro Computer CEO Says Don't Expect Negative Allocation From NVIDIA

Super Micro Computer CEO Says He Has An 'Open Mind' About Separating CEO And Chairman Roles

Gerdau Reports Q3 Adjusted EBITDA Of R$3.0B, Up 14.9% Q/Q

Murchinson Ltd. holds approximately 7.1% of the outstanding shares of Nano Dimension.

NNDM

Murchinson Urges Nano Dimension Shareholders To Vote For Its Independent Nominees; Sends Letter Highlighting Company's Questionable Acquisitions

TD Bank Expects Catastrophe Claims Of $388M After Reinsurance And Before Tax To Be Reflected In Wealth Management & Insurance Segment's Q4 Results

In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report), with a pr...

Stifel Nicolaus Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

IDEAYA Biosciences GAAP EPS of -$0.60 beats by $0.04

"This was a transformational quarter for Ideaya, including completion of an oversubscribed ~$302.4 million follow-on financing, a late breaker oral...

Ideaya Biosciences reports Q3 EPS (60c), consensus (63c)

IDEAYA Biosciences (IDYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Zhu from ...

Promising Developments and Strong Financial Position Drive IDEAYA Biosciences Buy Rating

Ideaya Biosciences ( ($IDYA) ) has released its Q3 earnings. Here is a breakdown of the information Ideaya Biosciences presented to its investors. ...

IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress

Warning: IDYA is at high risk of performing badly

Justin Zelin, an analyst from BTIG, maintained the Buy rating on IDEAYA Biosciences (IDYA – Research Report). The associated price target remains t...

Promising Developments in IDEAYA Biosciences: A Catalyst-Rich Future Supports Buy Rating

As previously reported, Leerink downgraded Ideaya Biosciences (IDYA) to Market Perform from Outperform with a price target of $27, down from $41, f...

Leerinks downgrades Ideaya Biosciences pending clarity on key programs

Leerink analyst Christopher Liu downgraded Ideaya Biosciences (IDYA) to Market Perform from Outperform with a $27 price target Published first on T...

Ideaya Biosciences downgraded to Market Perform from Outperform at Leerink

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Dollar Tree downgraded, eBay upgraded: Wall Street's top analyst calls

ALRM

CNTY

CVNA

DLTR

DNUT

EBAY

FSLR

FSUN

HMST

HUBB

IDYA

ROIC

Press Releases

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

Comments

IDEAYA Biosciences

IDEAYA Biosciences (IDYA) オプション

IDEAYA Biosciences (NASDAQ:IDYA) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル